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Abstract
Rotavirus is the leading cause of diarrheal disease in children under 5 years of age. It is responsible 
for more than 450,000 deaths each year, with more than 90% of these deaths occurring in low-
resource countries eligible for support by the GAVI Alliance. Significant efforts made by the 
Alliance and its partners are providing countries with the opportunity to introduce rotavirus 
vaccines into their national immunization programs, to help prevent childhood illness and death. 
We projected the cost-effectiveness and health impact of rotavirus vaccines in GAVI-eligible 
countries, to assist decision makers in prioritizing resources to achieve the greatest health benefits 
for their populations. A decision-analytic model was used to project the health outcomes and direct 
costs of a birth cohort in the target population, with and without a rotavirus vaccine. Current data 
on disease burden, vaccine efficacy, immunization rates, and costs were used in the model.  
Vaccination in GAVI-eligible countries would prevent 2.46 million childhood deaths and 83 
million disability-adjusted life years (DALYs) from 2011 to 2030, with annual reductions of 180,000 
childhood deaths at peak vaccine uptake. The cost per DALY averted is $42 for all GAVI countries 
combined, over the entire period. Rotavirus vaccination would be considered very cost-effective for 
the entire cohort of GAVI countries, and in each country individually, as cost-effectiveness ratios 
are less than the gross domestic product (GDP) per capita. Vaccination is most cost-effective and 
has the greatest impact in regions with high rotavirus mortality. Rotavirus vaccination in GAVI-
eligible countries is very cost-effective and is projected to substantially reduce childhood mortality 
in this population.
Richard D. Rheingans, Deborah E. Atherly, Kristen D.C. Lewis, Jacqueline Tate & Umesh D. Parashar 
(2012) "Projected Health And Economic Impact Of Rotavirus Vaccination In GAVI-Eligible Countries: 
2011–2030" Vaccine 30 pp.A7-A14 Version of Record Available From www.sciencedirect.com
1. Introduction
Diarrhea is the second-leading cause of childhood mortal-
ity worldwide, and is responsible for approximately 1.34 million 
deaths each year in children under 5 years of age [1]. Rotavirus is 
the primary cause of diarrheal disease in this population, account-
ing for 30–40% of diarrheal deaths [2]. Although the illness affects 
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ns children in every country, over 90% of the deaths occur in 
developing world. The introduction of effective rotavirus vaccin
creates the possibility of significantly reducing diarrheal m
tality and hospitalizations. Growing evidence from middle a
upper income countries where rotavirus vaccination has be
introduced, suggests that the vaccine is associated with reduc
hospitalizations and even death among children less than 5 ye
of age. According to recent reports from Europe, Australia a
the United States, reductions of 70–95% of hospitalizations 
rotavirus-specific diarrhea and 35–48% for all-cause diarrhea ha
occurred after the vaccine was introduced into routine immuni
tion programs [3–8]. These reductions in diarrheal hospitalizatio
have also been observed in lower-middle income countries in 
Latin America [9,10]. For the first time, real reductions in diar-
rheal deaths have also been recorded. In Mexico, researchers 
observed a 35% reduction in childhood diarrheal deaths after 
vaccine introduction, and in Brazil similar trends were seen 
[11–13].
In low-income countries that bear the vast majority of rotavirus
mortality, there is less direct evidence of the effectiveness of
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accination at scale, in part because many of these countries
re only now making decisions regarding national universal vac-
ination programs. Nicaragua introduced the vaccine into the
outine immunization schedule in 2006 – the first GAVI-eligible
ountry to do so. A 46% reduction against all rotavirus hospital-
zations was noted, as well as a 58% reduction in the number of
ases of severe rotavirus disease requiring intravenous (IV) fluids
14].
To make the decision to introduce new and relatively expen-
ive vaccines, policy makers will benefit from reliable estimates
f the costs and outcomes that might be attained through routine
mmunization. The best available estimates are typically based on a
ombination of regularly updated information on epidemiological
urden, vaccine efficacy, immunization delivery, effectiveness, vac-
ine demand, price, and economic burden. This includes a growing
umber of national level studies [15–18] as well as global analyses
19,20].
Improved estimates are essential for deciding whether to intro-
uce rotavirus vaccination but also how to do so. All such ex ante
nalyses have uncertainties associated with them, which can be
educed as new information becomes available. Since the publica-
ion of our earlier analysis of expected impacts in GAVI-eligible
ountries, additional data have emerged on the vaccine efficacy
n Africa and Asia [21–23], immunization delivery [24], epidemi-
logical burden of disease [1,2], and vaccine market dynamics such
s pricing and demand. Much of this new information will have
substantial influence on the cost-effectiveness and impact of
otavirus vaccines, thus highlighting the importance of an updated
nalysis.
. Methods
.1. ModelWe used an Excel-based model to estimate the economic and
ealth impact of rotavirus vaccination in GAVI-eligible countries
rom 2011 to 2030 [25]. Principal model inputs and their values are
isted in Table 1. Annual birth cohorts were followed for a five-year
able 1
odel parameters: values for base case scenario and ranges.
Parameter Base-case value
Health
5-year risk of rotavirus mortality Country-specific
5-year risk of rotavirus hospitalization 0.016
5-year risk of rotavirus outpatient visit 0.202
Average hospital length of stay 4 days
Years of life lost (YLL) per death-discounted,
age weighted
34
Years of life lived with disability (YLD) per
event-discounted, age-weighted
0.00037
Vaccine efficacy
Against severe rotavirus gastroenteritis
resulting in hospitalization or death (by
childhood mortality strata)
57% (high)
72% (mid)
85% (low)
Against all-severity rotavirus gastroenteritis
(by childhood mortality strata)
47% (high)
70% (mid)
78% (low)
Against severe all-cause gastroenteritis (high
childhood mortality setting)
24.8%
Efficacy of one dose 50% of full course
efficacy
Relative coverage 90%
Costs
Hospitalization unit cost $17–232
Outpatient unit cost $1–13
Vaccine program cost per dose $0.25–1.25period and the health outcomes and associated healthcare costs
of rotavirus both with and without vaccination, were estimated for
this population. GAVI-eligible countries were modeled individually
and results were grouped by World Health Organization (WHO)
region (see Table 2).
We conducted the analysis from a healthcare system perspec-
tive, focusing on costs and benefits to donors and governments.
We included direct medical costs from outpatient visits and
hospitalizations including the cost of diagnostic tests, medica-
tion, supplies, facilities, and personnel, as well as the cost of
vaccination. Costs of informal medical treatment, as well as indi-
rect medical and non-medical costs are not included in the
model.
We estimated health burden in terms of disability-adjusted life
years (DALYs) and deaths. DALYs quantify the years of life lost due
to premature death and the years lived with disability [26]. We cal-
culated DALYs due to rotavirus mortality based on the standardized
life expectancy at age one [27]. DALYs from rotavirus cases result-
ing in outpatient or hospital visits were calculated based on default
disability weights [26], an estimated illness duration of six days,
and were age-weighted [28,29].
Estimates of DALYs averted by universal rotavirus vaccination
were used to calculate the incremental cost-effectiveness ratio
(US$/DALY averted). Estimates are expressed in 2010 US dollars,
and all future costs and DALYs were discounted at a rate of 3%
annually.
2.2. Healthcare costs of rotavirus
Country-specific estimates of hospital and outpatient costs were
derived from WHO-CHOICE data [30], which standardizes costs
for healthcare visits according to the geographical region and
mortality stratum. We multiplied the per diem costs with an
average length of hospital stay of four days [19] and diagnos-
tic and medication costs were estimated as a proportion of the
per visit and per diem costs [31,32]. Cost estimates were con-
verted from Year 2005 international dollars to 2010 US dollars
using the Consumer Price Index [33] and official exchange rates
[34].
Range Source
±25% [55]
0.012–0.02 [37]
0.152–0.252 [37]
3–5 [19]
NA [56]
NA [56]
41–69% (high)
55–85% (mid)
70–94% (low)
[21–23,57–59]
32–60% (high)
56–80% (mid)
58–89% (low)
[21–23,57–59]
12.6–35.3% [21–23]
Assumption
60–100% Assumption
±25% WHO-CHOICE website
±25% WHO-CHOICE website
±25% [35]
Table 2
GAVI-eligible countries by WHO region.
AMR-Region of
the Americas
EUR-European
Region
AFR-African Region EMR-Eastern
Mediterranean Region
SEAR-Southeast
Asian Region
WPR-Western
Pacific Region
Bolivia Armenia Angola Lesotho Afghanistan Bangladesh Cambodia
Cuba Azerbaijan Benin Liberia Djibouti Bhutan Kiribati
Guyana Georgia Burkina Faso Madagascar Pakistan DPR Korea Lao PDR
Haiti Kyrgyzstan Burundi Malawi Somalia India Mongolia
Honduras Moldova Cameroon Mali Sudan Indonesia Papua New
Guinea
Nicaragua Tajikistan Central African Republic Mauritania Yemen Myanmar Solomon
Islands
Ukraine Chad Mozambique Nepal Vietnam
Uzbekistan Comoros Niger Sri Lanka
Congo Nigeria Timor-Leste
Congo DR Rwanda
Côte d’Ivoire São Tomé & Principe
Eritrea Senegal
Ethiopia Sierra Leone
Gambia Tanzania
The Ghana Togo
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Guinea Uganda
Guinea-Bissau Zambia
Kenya Zimbabw
.3. Vaccination program costs
Vaccination program costs include those costs associated with
toring, delivering and administering the vaccine once it arrives in
he country. The vaccine program costs were estimated using the
HO Global Immunization Vision and Strategy (GIVS) costing tool
35]. A program cost per dose was estimated for each of the coun-
ries, and a regional, weighted average was calculated and used in
he analysis.
.4. Health care utilization and mortality associated with
otavirus
We used updated country estimates of childhood deaths due to
iarrhea and rotavirus-specific illness, to revise the baseline disease
urden figures for our analysis [1,36]. We estimated rotavirus-
ssociated outpatient visits and hospitalizations by multiplying
he total diarrhea-related outpatient visits and hospitalizations by
he estimated proportion attributable to rotavirus [37]. Rotavirus
edical visits and deaths were distributed into the following age
ategories: 0–2 months, 3–5 months, 6–8 months, 9–11 months,
2–23 months, 24–35 months, 36–47 months, and 48–59 months
19].
.5. Vaccine efficacy
Recent clinical trials of rotavirus vaccine in sub-Saharan Africa
nd Southeast Asia found lower levels of vaccine efficacy than
bserved in trials in Latin America that were used in the original
odel [21–23]. As noted by the WHO Strategic Advisory Group of
xperts (SAGE), this finding is not unexpected [38] and is consistent
ith results from studies of other live, oral vaccines such as polio,
yphoid and cholera that suggest lower efficacy or immunogenic-
ty in developing country populations compared to industrialized
ountries [39–41].
Efficacy estimates against severe rotavirus diarrhea, any
otavirus diarrhea, and all-cause severe gastroenteritis for coun-
ries in the African and Asian regions were calculated and applied
y child mortality strata (see Table 1). Pooled random effects
ean estimates from the trials conducted in the high mortal-
ty countries of Ghana, Kenya, Bangladesh, South Africa, Malawi
nd Mali were applied to countries with under-5 mortality rates
30/1000. Estimates from the study in Vietnam were applied tocountries with child mortality rates ≤30/1000. Previous estimates
from trials in Latin America were still used for Latin American and
Caribbean countries. Estimates of efficacy against severe rotavirus
gastroenteritis are used as a proxy for efficacy against mortality and
hospitalization, and efficacy against any rotavirus gastroenteritis
corresponds to efficacy against outpatient visits.
2.6. Forecasted demand and price over time
Atherly et al. [19] demonstrated that estimates of the impact
and cost-effectiveness of vaccination over time depend heavily on
assumptions about which countries introduce vaccine, the timing
of their introduction and how price changes over time as a result of
market factors such as increased demand and the entry of new man-
ufacturers. Many countries have expressed interest in rotavirus
vaccines, leading several to apply for vaccine support from GAVI
[42]. Recent estimates have projected a total of over 40 country
introductions of rotavirus vaccine by 2015; this figure is in addition
to the five countries that introduced vaccine prior to 2012 [43,44].
Thus, for this analysis we have assumed that a total of 47 coun-
tries will adopt by 2015, based on current GAVI predictions. We
estimated that 17 of the remaining 25 countries would introduce
vaccine by 2020, and 8 countries after 2020. See Table 2 for the
complete list of countries. Some countries may graduate from GAVI
eligibility before or after they have introduced vaccine. However,
estimates of benefits and costs over the entire analysis timeframe
account for all expected rounds of vaccination in currently eligi-
ble countries assuming that graduating countries will be able to
adopt and/or sustain their rotavirus immunization programs after
graduation.
Vaccine prices were estimated from current and expected price
agreements between the purchasing agents for GAVI-eligible coun-
tries (UNICEF and PAHO), and the vaccine manufacturers. The
average price of rotavirus vaccine is expected to decline over the
analysis timeframe. In 2011, we used an initial vaccine price of
$7.50 per dose for a 2-dose regimen based on existing multina-
tional supplier contracts with low to middle-income countries and
their agents, in Latin America [45]. Between 2012 and 2015 we
used an estimated average price of $3.50 per dose for a 2-dose reg-
imen, based on pledges made by existing multinational suppliers
[46]. Beginning in 2016, the price falls to $2.00 and then to $1.50 in
2018, reflecting competition and price decline due to the projected
entry of products from developing country manufacturers [47].
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.7. Vaccine coverage and delivery
We estimated vaccine coverage using UNICEF/WHO best esti-
ates for DPT1 and DTP2 for each country. Then, updated estimates
n the timing of routine vaccinations from Clark et al. were incor-
orated [24]. We also assumed that the coverage rate for children
t the highest risk of rotavirus mortality was 90% of the vaccination
ate for other children, since children who die of diarrhea may have
ad less access to vaccination and other health care resources [48].
.8. Sensitivity analyses
One-way sensitivity analysis was conducted to assess the impact
f specific variables on the number of deaths averted and cost-
ffectiveness of vaccination. Variables included rotavirus mortality
ncidence, vaccine efficacy, relative coverage (the adjustment made
or inequitable vaccine access in those children most likely to die),
accination program costs, and timing of vaccine dosing.
A probabilistic uncertainty analysis was done to assess the com-
ined effect of multiple variables on vaccination impact (deaths
verted) and cost-effectiveness ($/DALY averted) in the base-case
nalysis. A Monte Carlo simulation was performed using distri-
utions for the key input variables, including rotavirus mortality,
accine efficacy, vaccination systems costs, and relative coverage.
ultiple iterations (10,000) randomly drew values from the input
ariable distributions and generated a distribution of output values
nd corresponding uncertainty limits (5th and 95th percentiles of
he output distributions).
.9. Scenario analyses
.9.1. Efficacy against severe all-cause gastroenteritis
Pooled data from the trials in Africa and Asia were used to esti-
ate the deaths averted and cost-effectiveness of vaccine against
evere, all-cause gastroenteritis. Since data from the Latin American
nd Caribbean (AMR) and European (EUR) regions were not avail-
ble, we used the base case estimates for rota-specific efficacy and
mpact in these regions, to allow us to report total GAVI estimates.
.9.2. Indirect benefits
For some vaccines, indirect protection through herd immunity
s an important determinant of impact as it benefits populations
ho may not be reached with routine vaccination [49]. There is
ome evidence from large scale introduction studies of rotavirus
accines that are consistent with indirect protection. For exam-
le, data from the United States, El Salvador and Australia indicate
able 3
ase-case results—impact and cost-effectiveness of the introduction of rotavirus vaccines
WHO region
AMR EUR AFR
Total number of deaths averted 39,140 24,270 1,352,870
Total DALYs averted 1,335,000 829,800 46,132,900
Impact per 1000 children vaccinated
DALYs averted 78 (58–84) 37 (20–45) 118(71–137)
Health care visits averted 145 125 85
Medical costs averted $2260 $2130 $600
Cost per DALY averted 2010 (US$)
Projected price trajectory
from 2011 to 2030 (confidence
range: 5–95%)
$63 ($44–90) $116 ($62–173) $38 ($26–55)
Range of lowest and highest
GDP per capita for countries
included in each region [60]
650–2600 720–2800 160–1200declines in rotavirus disease among older, unvaccinated children
[4,50,51]. Currently, there is insufficient evidence to firmly estab-
lish such an effect so we have not incorporated it into our base case
estimates of effectiveness. However, a scenario on indirect effects
has been included as a part of our sensitivity analysis. This indirect
effects scenario assumed that for each outcome, non-vaccinated
children would receive a level of protection proportional to the
efficacy in vaccinated children and the level of coverage. Specifi-
cally, we assumed that unvaccinated children would receive half
of the level of protection as vaccinated children, times the propor-
tion of children vaccinated. So at 50% coverage and 60% efficacy in
vaccinated children, unvaccinated would receive 15% protection,
while at 95% coverage, unvaccinated children would receive 28.5%
protection. These simplified assumptions are intended to provide
a preliminary estimate of the potential impact.
2.9.3. Constant vaccine price over time
Vaccine price is an important determinant of both cost-
effectiveness and affordability. The base case represents a price
trajectory over time, but it is also important to understand the
relative cost-effectiveness of vaccine at various set prices. We ran
scenarios to determine the cost-effectiveness of vaccination at
prices of $7.00, $5.00, $2.50 and $1.50 per dose, assuming those
prices remain constant through 2030.
3. Results
3.1. Base case: vaccine impact
Between 2011 and 2030, rotavirus vaccination for 72 GAVI-
eligible countries is projected to avert the deaths of more than
2.4 million children, and prevent more than 83 million disability-
adjusted life years (DALYs) (Table 3). Ranges for these figures,
calculated from probabilistic sensitivity analysis are 1.8–3 million
deaths and 54–95 million DALYs averted. More than 95% of the
averted burden would occur in the African (AFR), Eastern Mediter-
ranean (EMR) and Southeast Asian (SEAR) regions combined. For
every 1000 children vaccinated, 89 health care visits, $1000 in med-
ical expenses and 93 DALYs would be avoided. The health benefits
per 1000 children vaccinated vary widely, and are highest in the
GAVI-eligible countries of the Eastern Mediterranean (142 DALYs
averted) and African (118 DALYs averted) regions and lowest in
the Western Pacific region (13 DALYs averted). The EMR and AFR
regions include several high rotavirus mortality countries, while
seventy percent of the GAVI-eligible population in the WPR region
into GAVI-eligible countries from 2011 to 2030.
EMR SEAR WPR All GAVI
549,830 482,300 10,100 2,458,510
(1,800,000–3,000,000)
18,725,200 16,448,400 347,400 83,818,700
(54,000,000–95,000,000)
142(89–173) 52 (34–65) 13 (6–15) 93
(56–108)
85 87 114 89
$960 $1360 $885 $1000
$30 ($18–40) $60 ($45–90) $231 ($170–440) $42 ($31–64)
500–1300 400–1800 700–1300 150–2800
Table 4
Scenario analyses: vaccination impact and cost-effectiveness on all-cause diarrheal mortality, and with indirect effects; and cost-effectiveness at different vaccine prices, by
WHO region and all GAVI countries.
Region
AMR EUR AFR EMR SEAR WPR All GAVI
Base case scenario
Deaths averted 39,140 24,275 1,352,870 549,830 482,300 10,100 2,458,510
Cost/DALY averted $63 $116 $38 $30 $60 $231 $42
Scenario 1. All-cause diarrheal mortality
Deaths averted 39,140 24,275 1,786,000 590,300 505,540 10,300 2,955,555
Cost/DALY averted $63 $116 $30 $30 $66 $254 $39
Scenario 2. Indirect effects
Deaths averted 47,025 32,090 1,703,880 668,500 588,800 11,880 3,052,175
Cost/DALY averted $50 $78 $30 $25 $46 $190 $33
Scenario 3. Constant vaccine price over time: cost/DALY averted
$7.00 197 318 138 100 264 1152 176
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erage have a substantial impact on projected deaths averted,
whereas changes in the timing of vaccination have a more modest
effect.
Table 5
One-way sensitivity analysis showing the influence of selected variables on the cost-
effectiveness and impact of vaccination.
Deaths averted Cost/DAIY averted (US$)
Base case 2,458,510 42
RV mortality
Base 2,458,510 42
25% 3,073,000 32
−25% 1,844,000 54
Vaccine efficacy
Base 2,458,510 42
High 2,802,000 36
Low 1,936,210 56
Relative coverage
100% 2,729,000 37
Base – 90% 2,458,510 42
60% 1,647,000 62
Timing
Base – current 2,458,510 42
On-time 2,658,000 39$5.00 137 226 100
$2.50 61 111 53
$1.50 31 65 34
s represented by Vietnam, a country with good rotavirus surveil-
ance data and a very low rotavirus mortality rate.
Annual deaths averted rise sharply between 2011 and 2019 as
ountries are introducing vaccine into their national immunization
ystems (Fig. 1). Once full introduction and target vaccine cover-
ge is reached in all 72 countries, rotavirus vaccine is expected to
revent approximately 180,000 of the 429,000 estimated rotavirus
eaths each year in these countries, reaching a cumulative 2.46
illion deaths averted by 2030.
.2. Base case: cost-effectiveness
Under the base case scenario, the cost-effectiveness of rotavirus
accination is $42/per DALY averted. Cost-effectiveness ratios were
ighest in the Western Pacific region ($231) and lowest in the East-
rn Mediterranean ($30). The World Health Report suggests that
n intervention averting one DALY at a cost that is less than the
DP per capita, is very cost-effective. Those averting each DALY at a
ost between one and three times the GDP per capita are cost effec-
ive [52]. Based on this threshold, rotavirus vaccination under the
ase-case scenario, is very cost-effective in every region. The lowest
DP per capita in each region (representing the poorest country) is
igher than the CE ratio for that region, and is higher than the upper
alue of the confidence range as well, suggesting that vaccina-
ion is very cost-effective in all 72 countries. The cost-effectiveness
ecreases over time as the number of infants vaccinated increases
Fig. 2). The higher ratios in the first two years are primarily driven
y a higher vaccine price and the presence of vaccination programs
n relatively lower burden countries of Latin America. As time pro-
resses, the price drops dramatically and higher-burden countries
egin to introduce the vaccine, leading to lower, more favorable
ost-effectiveness ratios.
.3. Scenario analysis
Under an alternative scenario including all-cause diarrhea mor-
ality, rotavirus vaccination is projected to avert more than 2.9
illion deaths associated with all causes of diarrhea, with 60%
f the impact occurring in the African region (Table 4). The cost-
ffectiveness is $39 per DALY averted for all regions combined, with
high of $254 in the Western Pacific region and low of $30 in the
frican and Eastern Mediterranean regions, meeting the thresh-
ld for a very-cost-effective intervention at the global and regional
evels. Under a scenario that assumes indirect benefits of vaccina-
ion, rotavirus vaccine is once again, very cost-effective and could71 185 815 125
36 87 394 62
22 48 225 37
avert the deaths of an estimated 3 million children in GAVI-eligible
countries.
Vaccination remains very cost-effective for all GAVI countries
combined, under all price scenarios. At $7.00 per dose, the cost per
DALY averted is $176, and at a low of $1.50 per dose, the incremental
CE ratio is $37. Regionally, vaccination is very-cost-effective in all
regions at all price levels, with the exception of the Western Pacific
region, where it is between one and three times GDP at prices of
$7.00 and $5.00 per dose.
3.4. One-way sensitivity analysis
Only small changes in the cost-effectiveness of vaccination
occurred when values for key variables were changed (Table 5). The
CE ratio increases to a high of $62 when relative coverage decreases
to 60% and the ratio declines to a low of $32 when rotavirus
mortality estimates are increased by 25%. Variations in estimates
of vaccine efficacy, baseline rotavirus mortality and relative cov-Vaccination system cost
Base – GIVS 2,458,510 42
50% N/A 48
−50% N/A 36
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Fig. 1. Annual and cumula
. Discussion
This analysis focuses specifically on estimating the health
mpact and cost-effectiveness of rotavirus vaccination in GAVI-
ligible countries, utilizing recent developments in the field. We
ave incorporated the reported vaccine efficacy data from low-
esource settings in Africa and Asia, utilizing pooled estimates
ased on Under5 mortality strata [53]. We have used the recently
pdated WHO estimates for rotavirus mortality, which are slightly
ower than previously reported [36]. In addition, this analysis cap-
ures evolutions in market dynamics such as the increased demand
or vaccine in high-burden countries and reductions in vaccine
rices. There has been a surge in country applications from GAVI-
ligible countries for rotavirus vaccines, and the first in Africa –
orth Sudan – initiated rotavirus immunization in the national
hildhood immunization schedule in July 2011 [42].
The 72 countries included in this analysis carry nearly 95% of
he burden of rotavirus mortality, accounting for approximately
29,000 annual deaths in young children under five. The intro-
uction of rotavirus vaccines in these GAVI-eligible countries will
ave significant public health impact in terms of deaths and
ospitalizations averted, and would be considered a very cost-
ffective intervention. Rotavirus immunization could avert the
eaths of 2.46 million children in these countries between 2011 and
030. Cost-effectiveness improves rapidly in the early years, when
0.0
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Fig. 2. Annual cost-effectiveness ratio and nueaths averted, 2011–2030.
vaccine price reductions are anticipated and high-mortality coun-
tries begin to introduce vaccine.
Rotavirus vaccines have demonstrated modest vaccine efficacy
in resource poor settings with the highest rates of Under5 mortal-
ity and rotavirus associated mortality [21–23]. Annual reduction
of 180,000 childhood deaths could be expected in these countries,
representing a 42% reduction in total rotavirus mortality. Lower
vaccine efficacy in high burden countries is the primary factor limit-
ing overall impact. However, 98% of the estimated rotavirus deaths
averted among these countries occur in those with the highest rates
of childhood death and lowest vaccine efficacy. For instance, the 10
countries with the highest rates of rotavirus mortality per capita
(>300/100,000) are in Africa and the Middle East. These would
experience the greatest benefit from the introduction of rotavirus
vaccines. So despite lower efficacy, the public health impact will be
enormous in those countries with the greatest burden.
Regional variations in the cost-effectiveness and public health
impact of rotavirus vaccination were observed in this analysis.
These regional differences in cost-effectiveness and health out-
comes are more influenced by underlying disease burden than
by vaccine efficacy. For example, despite lower estimated vac-
cine efficacy in the African and Eastern Mediterranean populations,
the vaccine has the greatest public health impact – measured by
DALYs averted per 1000 children vaccinated – and is the most cost-
effective in these regions that carry the highest rotavirus mortality
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ates. In contrast, countries included in the Western Pacific region
ave the lowest average mortality rate, and although higher vac-
ine efficacy estimates were applied to this population, the health
mpact is smaller and the cost-effectiveness ratio is higher com-
ared to other regions.
Of global health importance is the overall impact of rotavirus
accines on all-cause severe diarrheal morbidity and mortality.
pplying the figure of 24.8% vaccine efficacy against all-cause
evere gastroenteritis deaths (pooled estimate as described above),
ields estimates of the impact of vaccine that are 20% higher than
he base case results of 2.46 million rotavirus deaths averted. The
ifference may be explained, in part, by undetected rotavirus in
he populations from which these all-cause diarrhea efficacy results
ere derived, due to late presentation in the course of the diarrheal
pisode and/or limited diagnostic sensitivity of the ELISA system
sed. The variance may also be due to an overestimate of vaccine
fficacy against all-cause severe gastroenteritis in the clinical tri-
ls. For example, if all-cause efficacy was measured only through
he rotavirus season and then annualized, the estimate would be
alsely high.
Results from the scenario that modeled the indirect effects of
accination suggest that the impact may be greater than estimated
n the base case. The 25% increase in deaths averted is dependent
pon the simplifying assumptions used in modeling this scenario.
t is not surprising that impact expands, since more children are
enefiting from vaccination compared to the base case. In addi-
ion to improving overall impact, indirect protection may also
ncrease equity by providing protection to higher risk children who
ould not otherwise be vaccinated. However this would likely
epend on proximity and other population dynamics between vac-
inated and unvaccinated children, and needs to be examined in the
eld.
This study has some limitations. We used DPT vaccine coverage
s a proxy for rotavirus vaccines; however, we did not include the
otential impact on coverage by the age restrictions placed on the
iming of administration of rotavirus vaccines [54]. The restrictions
ay decrease overall coverage, and therefore impact, compared
o that achieved with DPT, but these data will only be available
fter countries have introduced. We did lower DPT coverage rates
n our base case analysis though, to account for the assumption that
here may be inequity in vaccine coverage, especially for those most
ikely to die from rotavirus, thus resulting in a more conservative
stimate. As more data become available, these coverage assump-
ions will become more refined and accurate. In addition, although
e have used available data and historical trends to project coun-
ry introductions, it is very difficult to accurately predict adoption
atterns, particularly more than a few years in the future. We
ave illustrated a snapshot of one potential demand scenario that
ttempts to capture the impact of rotavirus vaccines in all GAVI-
ligible countries. However, changes in the timing and inclusion
f country introductions will occur as time goes on, so updated
nalyses will be required to reflect the impact of these changes.
This analysis strongly supports the WHO recommendation for
he introduction of the live, oral rotavirus vaccines in countries
ith high Under5 mortality, high diarrheal incidence and limited
ealth resources. Rotavirus immunization is very cost effective
nd has significant public health impact in the GAVI-eligible coun-
ries which carry the greatest burden of rotavirus morbidity and
ortality. Rotavirus vaccines are utilized in several middle- and
igh-income countries where there has been a dramatic decline
n rotavirus associated hospitalizations and savings to the medi-
al health system. As the GAVI Alliance is bridging the funding gap
or new vaccines, and many countries are applying for financial
upport, the major impact of rotavirus vaccines on child mor-
ality and health in the hardest hit populations may soon be
ealized.
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